Drug intelligence / Profile preview

Tanzânia association

Development stage: Phase 3
Modality: Small Molecules

Overview

Tanzânia association is a therapeutic combination being investigated for the treatment of erectile dysfunction associated with benign prostatic hyperplasia. The specific components and mechanism of action of this 'association' are not publicly disclosed, and 'Tanzânia' itself does not appear to be a recognized drug name but rather a placeholder or a descriptor for the combination therapy. Clinical trials evaluating its efficacy and safety for these conditions have been completed.

Brand names: Tanzânia
Other names: Tanzânia associationtadalafil + tamsulosinTamsulosin + Tadalafil

Targets

PDE2 (Phosphodiesterase 2)ADRA1A (α1A)ADRA1D (α1D)PDE6 (Phosphodiesterase 6)PDE5 (Phosphodiesterase 5A)PDE3ADRA1B (α1B)PDE1 (Phosphodiesterase 1)PDE11A (Phosphodiesterase 11A)PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on Tanzânia association.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tanzânia association.

Explore the full profile